Sector News

Who’ll follow Sanofi CEO Olivier Brandicourt? The company’s eyeing candidates now

March 21, 2019
Life sciences

It’s been a tumultuous four years for Olivier Brandicourt at Sanofi, marked by restructuring, cost cuts, an asset swap and two M&A deals designed to upgrade the drugmaker’s rare disease business. What happens over the next four years is anybody’s guess, but the company’s working now to decide who’ll be at the helm, a spokeswoman said.

Sanofi is planning for Brandicourt’s departure because he’s two years away from his 65th birthday, and the company “sets the end of its CEO assignment at the age of 65,” the spokeswoman added.

“With this perspective, the board has been considering this succession plan for some time now, in agreement and consultation with our CEO,” Sanofi’s spokeswoman said.

Sources told Reuters that talks about the company’s future leadership have grown more intense in recent weeks. In February, Sanofi reported a sales decline for 2018, and just last week, the company disclosed it had cut Brandicourt’s pay by 25% to €7.28 million ($8.2 million), making his the smallest compensation package in Big Pharma.

Brandicourt has served as Sanofi’s CEO since April 2015, when he was brought in to lead the company after the board fired Chris Viehbacher, amid tensions over his leadership style. Brandicourt inherited a company facing intense pricing pressure in its key diabetes unit and a thin pipeline of new drug candidates.

Soon after taking the helm, he unveiled a restructuring plan to cut costs and jobs, focus on five business units and emphasize its rare disease group Genzyme.

He also started shopping for deals, with mixed results; the company lost out on Medivation in 2016 when Pfizer swooped in, and Actelion snubbed its takeover attempts before hooking up with Johnson & Johnson. But in 2016 Sanofi did ink an asset swap with Boehringer Ingelheim, sending away Sanofi’s animal health business in exchange for Boehringer’s consumer healthcare unit.

And in early 2018, Sanofi struck deals for Ablynx and Bioverativ in quick order, boosting its presence in rare blood diseases. Sanofi’s first med from the Ablynx deal, Cablivi, recently scored an FDA nod and carries peak sales estimates of $500 million.

Genzyme has delivered on a couple of other fronts, too. Dupixent, a Regeneron-partnered atopic dermatitis therapy approved in 2017, grew to €783 million ($887 million) last year. The drug has snagged new approvals in asthma and pediatric eczema patients, and it’s working on an indication in severe sinusitis. Kevzara, another Regeneron-partnered med, rolled out in 2017, with less success.

And one key launch under Brandicourt hasn’t panned out at all, at least not yet. The company’s dengue shot Dengvaxia, one of Viehbacher’s favorite projects, has been more of a liability than a sales engine as a safety controversy in the Philippines continues to generate negative headlines.

Sanofi isn’t the only drugmaker that’s had to contemplate replacing a retirement-age CEO over the past couple years. Last year, Merck & Co. changed its mandatory retirement rules to allow CEO Ken Frazier to stay in his post after he turns 65 this December.

And in 2017, Pfizer handed then-CEO Ian Read, who was eligible to retire at the time, an $8 million retention package to persuade him to stick around until March of this year; he bowed out as of Dec. 31, 2018, for new CEO Albert Bourla.

By Eric Sagonowsky

Source: Fierce Pharma

Join the discussion!

Your email address will not be published. Required fields are marked *

Related News

January 17, 2021

SII expects WHO emergency approval of Covid-19 vaccine soon

Life sciences

The Serum Institute of India (SII) expects to soon receive World Health Organisation (WHO) emergency use authorisation for the Oxford University/AstraZeneca Covid-19 vaccine, produced for mid and low-income countries.

January 17, 2021

Sanofi to acquire clinical-stage biopharma firm Kymab for $1.45bn

Life sciences

According to the deal, Sanofi will gain full global rights to Kymab’s fully human monoclonal antibody, KY1005 that attaches to OX40-Ligand and can potentially treat various immune-mediated diseases and inflammatory ailments.

January 17, 2021

Moderna poaches Amgen vet as CCO, jump-starting commercial team as it rolls out COVID-19 vaccine

Life sciences

Moderna tapped veteran Amgen executive Corinne Le Goff to spearhead that effort as chief commercial officer.

Send this to a friend